^
    CGP use in heme cancers offers both clinical and practical utility, particularly for diagnosis and prognosis, as well as for therapeutic guidance. CGP optimizes the testing strategy by comprehensively covering all clinically relevant genes, including both diagnostic and prognostic markers and markers that may influence participation in clinical trials.
    Cancer:
    Acute Myelogenous Leukemia
    Gene:
    FLT3 (Fms-related tyrosine kinase 3)
    Method:
    Next-Generation Sequencing (NGS)